Andrew King, BVMS, Ph.D.

Dr. King is Jade Biosciences’ Chief Scientific Officer & Head of Research and Development. Prior to his involvement in founding Jade, Dr. King served as Chief Scientific Officer at Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company that was acquired by Novartis AG, where he was responsible for overseeing the discovery research, non-clinical development, translational medicine and early clinical development teams, and played a lead role in late-stage clinical development strategy as chair or co-chair of the development review committee and as a sponsor representative on the company’s global Phase 3 clinical trial steering committees.  Prior to serving as Chief Scientific Officer, Dr. King served as Head of Renal Discovery and Translational Medicine for Chinook Therapeutics.Prior to joining Chinook, Dr. King served as the Executive Vice President of Discovery at BIOAGE Labs, a private biotechnology company, and as the Senior Director of Discovery and Translational Biology at Ardelyx, Inc. (Nasdaq: ARDX), a biotechnology company, where he focused on delivering small molecule candidates for the treatment of cardio-renal, metabolic and gastrointestinal diseases and made contributions to the approval of XPHOZAH® and IBSRELA®, including elucidating their novel mechanisms of action. Prior to Ardelyx, Inc., Dr. King was a Principal Research Scientist at AbbVie Inc. (NYSE: ABBV), where he led the Renal Discovery scientific strategy after serving in positions of increasing responsibility at Abbott Laboratories (NYSE: ABT).  Dr. King received a B.Sc. in Veterinary Biology from Murdoch University in Australia, a BVMS from Murdoch University in Australia and a Ph.D. in Pharmacology and Toxicology from Michigan State University.